What did Teleflex, Inc. pay for BIOTRONIK Vascular Intervention Business?

Teleflex, Inc. acquired BIOTRONIK Vascular Intervention Business for $875.9M in 2025 (9.5x EBITDA), equivalent to 2.20x revenue. Target revenue was approximately $408.0M. Target EBITDA was approximately $92.2M.

What does BIOTRONIK Vascular Intervention Business do?

BIOTRONIK Vascular Intervention Business is a medical devices business.

What multiple did Teleflex, Inc. pay for BIOTRONIK Vascular Intervention Business?

9.5x EBITDA and 2.20x revenue, based on disclosed deal value of $875.9M and disclosed financials.

M&A TRANSACTION · 2025

BIOTRONIK Vascular Intervention Business acquired by Teleflex, Inc.

$875.9M· 9.5x EBITDA· 2.20x revenue

Target

BIOTRONIK Vascular Intervention Business

Acquirer

Teleflex, Inc.

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$408.0M

EBITDA

$92.2M

Deal Value

$875.9M

EV/EBITDA

9.5x

Context

This $875.9M acquisition of BIOTRONIK Vascular Intervention Business by Teleflex, Inc. sits in the medical devices sub-vertical. The 9.5x EBITDA multiple paid in 2025 can be compared against the population median for medical devices transactions of similar size on our Medical Devices valuation hub. Teleflex, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price medical devices businesses on our Medical Devices strategic buyer-pool page.

Source

Data sourced from SEC filings and press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the BIOTRONIK Vascular Intervention Business acquisition.

Citation: ExitValue.ai. (2025). BIOTRONIK Vascular Intervention Business acquired by Teleflex, Inc.. https://exitvalue.ai/deals/biotronik-vascular-intervention-business-acquired-by-teleflex-inc-hc-2025-0015